Gregory Roloff, MD, The University of Chicago Medicine, Chicago, IL, provides an insight into the real-world outcomes of adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) who were treated with brexucabtagene autoleucel (brexu-cel), the only CAR T-cell product approved by the FDA for use in this patient population. This collaborative retrospective study pooled data from 25 institutions to investigate the clinical outcomes and safety profile of brexu-cel in these heavily pretreated patients who had received a median of four prior lines of therapy. High complete remission (CR) rates were observed, with around 80% of responders achieving measurable residual disease (MRD)-negativity. The majority of patients experienced cytokine release syndrome (CRS), although this was predominantly low grade; however, almost a third of patients suffered from high-grade immune effector cell-associated neurotoxicity syndrome (ICANS). Dr Roloff highlights the predictors of achieving a response, as several factors that resulted in superior or inferior outcomes were identified. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
